keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#1
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28333878/one-year-results-of-half-versus-standard-dose-photodynamic-therapy-combined-with-ranibizumab-for-polypoidal-choroidal-vasculopathy
#2
Ian Y Wong, Xuan Shi, Rita Gangwani, Lawrence P Iu, Nicholas Fung, Qing Li, Alex L K Ng, Xiaoxin Li
PURPOSE: To explore the efficacy of half-dose verteporfin photodynamic therapy (hd-PDT) and standard-dose photodynamic therapy (sd-PDT), when combined with ranibizumab in the treatment of polypoidal choroidal vasculopathy. METHODS: Subjects were allocated to either the hd-PDT arm or the sd-PDT arm. All subjects received an injection of ranibizumab and PDT treatment (dosage according to allocation) at baseline. Subjects were followed up monthly for 12 months, and re-treatment were given at each visit if criteria were met...
March 22, 2017: Retina
https://www.readbyqxmd.com/read/28333783/dome-shaped-macula-in-myopic-eyes-twelve-month-follow-up
#3
Daniel Lorenzo, Luis Arias, Netan Choudhry, Eduard Millan, Ignacio Flores, Marcos J Rubio, Estefanía Cobos, Pere García-Bru, Alejandro Filloy, Josep M Caminal
PURPOSE: To study the long-term clinical course of dome-shaped macula in myopic eyes and to evaluate treatment efficacy for subretinal fluid (SRF) as a related complication. METHODS: A retrospective, single-center consecutive case series study was conducted. The authors analyzed myopic eyes with dome-shaped macula in patients who presented for evaluation of decreased vision. Dome-shaped macula was defined as a convexity of the retina-choroidal macular complex seen on spectral domain optical coherence tomography images...
April 2017: Retina
https://www.readbyqxmd.com/read/28332616/long-acting-protein-drugs-for-the-treatment-of-ocular-diseases
#4
Joy G Ghosh, Andrew A Nguyen, Chad E Bigelow, Stephen Poor, Yubin Qiu, Nalini Rangaswamy, Richard Ornberg, Brittany Jackson, Howard Mak, Tucker Ezell, Vania Kenanova, Elisa de la Cruz, Ana Carrion, Bijan Etemad-Gilbertson, Roxana Garcia Caro, Kan Zhu, Vinney George, Jirong Bai, Radhika Sharma-Nahar, Siyuan Shen, Yiqin Wang, Kulandayan K Subramanian, Elizabeth Fassbender, Michael Maker, Shawn Hanks, Joanna Vrouvlianis, Barrett Leehy, Debby Long, Melissa Prentiss, Viral Kansara, Bruce Jaffee, Thaddeus P Dryja, Michael Roguska
Protein drugs that neutralize vascular endothelial growth factor (VEGF), such as aflibercept or ranibizumab, rescue vision in patients with retinal vascular diseases. Nonetheless, optimal visual outcomes require intraocular injections as frequently as every month. Here we report a method to extend the intravitreal half-life of protein drugs as an alternative to either encapsulation or chemical modifications with polymers. We combine a 97-amino-acid peptide of human origin that binds hyaluronan, a major macromolecular component of the eye's vitreous, with therapeutic antibodies and proteins...
March 23, 2017: Nature Communications
https://www.readbyqxmd.com/read/28324878/comparison-of-the-12-month-outcomes-of-intravitreal-ranibizumab-between-two-angiographic-subtypes-of-polypoidal-choroidal-vasculopathy
#5
Shunichiro Nakai, Shigeru Honda, Akiko Miki, Wataru Matsumiya, Makoto Nakamura
BACKGROUND: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). METHODS: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR...
March 22, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28324452/a-review-of-ranibizumab-for-the-treatment-of-diabetic-retinopathy
#6
REVIEW
Michael W Stewart
INTRODUCTION: Laser photocoagulation has been the standard treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) for several decades. The discovery of vascular endothelial growth factor (VEGF) and the subsequent determination of its critical role in the development DME and PDR has led to the development of VEGF inhibitory drugs. Ranibizumab was the first anti-VEGF drug approved for the treatment of both DME and diabetic retinopathy in eyes with DME. METHODS: Medline searches with the keywords "ranibizumab," "diabetic macular edema," and "proliferative diabetic retinopathy" were performed to identify pertinent pre-clinical studies and clinical trials...
March 21, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/28324112/recurrence-of-retinopathy-of-prematurity-after-intravitreal-ranibizumab-monotherapy-timing-and-risk-factors
#7
Jiao Lyu, Qi Zhang, Chun-Li Chen, Yu Xu, Xun-Da Ji, Jia-Kai Li, Qiu-Jing Huang, Pei-Quan Zhao
Purpose: To investigate timing and risk factors of recurrent retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) monotherapy. Methods: Fifty eyes (the more severe eye) of 50 infants treated with IVR monotherapy for type 1 ROP were studied retrospectively. The mean follow-up time was 31 weeks after IVR. Recurrent ROP (recurrence of extraretinal fibrovascular proliferation [EFP]) was determined by RetCam wide-angle fundus imaging and binocular indirect ophthalmoscopy...
March 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28323678/long-time-outcome-in-patients-treated-with-ranibizumab-for-diabetic-macular-edema-a-4-year-study
#8
David Epstein, Urban Amrén
PURPOSE: To investigate the long-time visual outcome in patients with diabetic macular edema treated with ranibizumab in an ordinary clinical setting. METHODS: One hundred two eyes of 80 patients were followed for 4 years. All patients received a loading dose of 3 monthly ranibizumab 0.5-mg injections. From Month 3 to Month 48, patients received ranibizumab reinjections pro re nata based on disease activity. RESULTS: Excluding deaths, the 4-year visit was completed by 82% of the study eyes...
January 23, 2017: Retina
https://www.readbyqxmd.com/read/28316836/comparison-of-progression-rate-of-retinal-pigment-epithelium-loss-in-patients-with-neovascular-age-related-macular-degeneration-treated-with-ranibizumab-and-aflibercept
#9
Juliana Wons, Magdalena A Wirth, Nicole Graf, Matthias D Becker, Stephan Michels
Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n = 17) or on switch date (n = 19)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#10
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315512/comments-to-clinical-experience-of-switching-anti-vegf-therapy-from-ranibizumab-to-aflibercept-in-age-related-choroidal-neovascularization
#11
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
March 7, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28306392/effect-of-syringe-design-on-the-accuracy-and-precision-of-intravitreal-injections-of-anti-vegf-agents
#12
Elad Moisseiev, Jolene Rudell, Eric V Tieu, Glenn Yiu
PURPOSE: To evaluate the accuracy and precision of different syringe designs for intravitreal injection of anti-VEGF agents. METHODS: Volume output was measured from three syringe designs-1) 1.0 mL tuberculin syringe, 2) 1.0 mL syringe with low dead space plunger, and 3) 0.5 mL low-volume syringe-to deliver 50 µL of bevacizumab, ranibizumab, or aflibercept, each repeated four times by three different physicians for 108 total simulated injections. Volume output was calculated from difference in syringe weight before and after expelling the drug...
March 17, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28304383/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#13
D Călugăru, M Călugăru
No abstract text is available yet for this article.
March 17, 2017: Eye
https://www.readbyqxmd.com/read/28301410/allergic-reaction-upon-intravitreal-administration-of-anti-vascular-endothelial-growth-factor-agents
#14
Gavin G Meredith, Paul A Schkade, Brian C Joondeph
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#15
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28292270/short-term-effects-of-intravitreal-ranibizumab-therapy-on-diabetic-macular-edema
#16
Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa, Akitoshi Yoshida
BACKGROUND: The short-term effects of intravitreal ranibizumab (IVR) on diabetic macular edema (DME) remains unclear. We assessed the short-term effects of IVR on DME. METHODS: Eighteen eyes of 14 patients with DME were enrolled in this prospective interventional case series. After intravitreal ranibizumab was injected into treatment-naïve eyes with DME, we measured the foveal thickness (FT) before and 2 h, 1 day, 1 week, and 1 month later and the best-corrected visual acuity (BCVA) at all times except 2 h and compared the changes to baseline (ΔFT and ΔVA)...
March 14, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28291194/-clinical-associations-between-photoreceptor-status-and-visual-outcomes-in-diabetic-macular-edema
#17
A Zh Fursova, N V Chubar', M S Tarasov, I F Saifullina, G G Pustovaya
AIM: to investigate morphological changes and visual acuity response to ranibizumab therapy in patients with different OCT-types of diabetic macular edema (DME) as well as different state of the inner and outer photoreceptor segments (IS and OS) and the outer limiting membrane (OLM); to study relationships between functional and morphological parameters before and after the treatment; to study the effect of glycated hemoglobin levels on morphological parameters and ME duration. MATERIAL AND METHODS: The study included 113 patients (113 eyes) with DME, who underwent 3 once-monthly intravitreal injections of ranibizumab (the mean patient age, 63...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28289548/the-comparative-effectiveness-and-cost-effectiveness-of-ranibizumab-for-neovascular-macular-degeneration-revisited
#18
Gary C Brown, Melissa M Brown, Heidi B Lieske, Adam Turpcu, Yamina Rajput
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascular, age-related macular degeneration (AMD). METHODS: Value-Based Medicine(®), 12-year, combined-eye model, cost-utility analysis employing MARINA and HORIZON clinical trial data...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28284785/the-clinical-importance-of-changes-in-diabetic-retinopathy-severity-score
#19
Michael S Ip, Jiameng Zhang, Jason S Ehrlich
PURPOSE: To investigate the clinical importance of changes in diabetic retinopathy severity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizumab. DESIGN: Post hoc analysis of the phase III RIDE and RISE studies of ranibizumab for treatment of DME. PARTICIPANTS: Four hundred sixty-eight eyes treated with ranibizumab from randomization with gradable DRSS on baseline fundus photographs. METHODS: Visual and anatomic outcomes were examined in eyes grouped according to DRSS change from baseline to month 24...
March 8, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28277877/results-of-intravitreal-ranibizumab-treatment-for-retinopathy-of-prematurity-in-infants
#20
Emine Alyamaç Sukgen, Yusuf Koçluk
PURPOSE: To assess the results of intravitreal ranibizumab treatment for retinopathy of prematurity (ROP) in infants. METHODS: A single-institution, retrospective consecutive case series. RESULTS: Thirty-one patients who received ranibizumab treatment for ROP were evaluated in this study. The mean follow-up time was 14 ± 1.37 months. Vascularization of the peripheral retina had completed with delay in the majority of cases and also avascular areas were present in the peripheral retinas of five infants at one year of age...
March 6, 2017: Cutaneous and Ocular Toxicology
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"